Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study | Zendy

Eline A.J. Willemse | Zendy; Ann De Vos | Zendy; Elizabeth Herries | Zendy; Ulf Andréasson | Zendy; Sebastiaan Engelborghs | Zendy; Wiesje M. van der Flier | Zendy; Philip Scheltens | Zendy; Dan L. Crimmins | Zendy; Jack H. Ladenson | Zendy; Eugeen Vanmechelen | Zendy; Henrik Zetterberg | Zendy; Anne M. Fagan | Zendy; Kaj Blennow | Zendy; Maria Bjerke | Zendy; Charlotte E. Teunissen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

Author(s) -

Eline A.J. Willemse,

Ann De Vos,

Elizabeth Herries,

Ulf Andréasson,

Sebastiaan Engelborghs,

Wiesje M. van der Flier,

Philip Scheltens,

Dan L. Crimmins,

Jack H. Ladenson,

Eugeen Vanmechelen,

Henrik Zetterberg,

Anne M. Fagan,

Kaj Blennow,

Maria Bjerke,

Charlotte E. Teunissen

Publication year - 2018

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2017.283028

Subject(s) - neurogranin , biomarker , cerebrospinal fluid , dementia , medicine , frontotemporal dementia , pathology , oncology , psychology , disease , endocrinology , chemistry , biochemistry , protein kinase c , enzyme

Neurogranin in cerebrospinal fluid (CSF) correlates with cognitive decline and is a potential novel biomarker for Alzheimer disease (AD) dementia. We investigated the analytical and diagnostic performance of 3 commonly used neurogranin assays in the same cohort of patients to improve the interpretability of CSF neurogranin test results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research